propidium has been researched along with alitretinoin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Blauberger, S; Ganslmayer, M; Hahn, EG; Herold, C; Ocker, M; Schuppan, D; Zopf, S | 1 |
Cui, T; Liu, L; Liu, Y; Mou, J; Pei, DS; Zhang, SN; Zhu, ZA | 1 |
2 other study(ies) available for propidium and alitretinoin
Article | Year |
---|---|
Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells.
Topics: Alitretinoin; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Bromodeoxyuridine; Carcinoma; Caspase 3; Caspases; Cell Division; Cell Line, Tumor; Cell Separation; Ciprofloxacin; Colonic Neoplasms; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunohistochemistry; Indicators and Reagents; Kinetics; Prognosis; Propidium; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Time Factors; Tretinoin | 2003 |
Combinational effect of PPARĪ³ agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro.
Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Chromans; Down-Regulation; Humans; Hypoglycemic Agents; Intercalating Agents; PPAR gamma; Propidium; Proto-Oncogene Proteins c-bcl-2; Retinoid X Receptors; Stomach Neoplasms; Thiazolidinediones; Tretinoin; Troglitazone; Up-Regulation | 2013 |